Drug Trial Radar · NCT03396445
Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001)
Last checked: Nov 19, 2026Latest source record: Nov 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
182
Actual
Start
Feb 18, 2018
Primary completion
Sep 27, 2024
Study completion Sep 27, 2024
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Jan 11, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety and pharmacokinetics of boserolimab (MK-5890) when administered alone and in combination with pembrolizumab (MK-3475) in adults. Boserolimab monotherapy or boserolimab plus pembrolizumab combination therapy will be administered in adults with advanced solid tumors, including endometrial cancer, for up to 35 administrations (approximately 2 years). The safety and pharmacokinetics of boserolimab when administered with pembrolizumab, pemetrexed and carboplatin in adults with non-squamous non-small cell lung cancer (NSCLC) and boserolimab when administered with pembrolizumab and nab-paclitaxel in adults with triple-negative breast cancer (TNBC) will also be assessed.
Conditions
- Pharmacokinetics
- Solid Tumor
- Carcinoma, Non-Small-Cell Lung
- Triple Negative Breast Neoplasms
Interventions
BoserolimabDrug
IV infusion
PembrolizumabBiological
IV infusion
PemetrexedDrug
IV infusion
CarboplatinDrug
IV infusion
Nab-paclitaxelDrug
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Experienced a Dose-Limiting Toxicity (DLT)Time frame: Up to 21 days in Cycle 1
- Number of Participants With One or More AEsTime frame: Up to approximately 78 months
- Number of Participants Who Discontinued Study Treatment Due to an AETime frame: Up to 23 months
Locations
18 sites in 7 countries. Site status is shown where the registry gives one.
University of South Alabama, Mitchell Cancer Institute ( Site 0020)
Mobile, Alabama
Florida Cancer Specialists ( Site 0002)
Sarasota, Florida
The West Clinic, P.C. ( Site 0021)
Germantown, Tennessee
FALP-UIDO ( Site 0502)
Santiago, Region M. de Santiago, Chile
Bradfordhill-Clinical Area ( Site 0501)
Santiago, Region M. de Santiago, Chile
Soroka Medical Center-Oncology ( Site 0012)
Beersheba, Israel
Hadassah Ein Kerem Medical Center ( Site 0010)
Jerusalem, Israel
The Chaim Sheba Medical Center - Oncology Institute ( Site 0001)
Ramat Gan, Israel
Antoni van Leeuwenhoek Ziekenhuis ( Site 0003)
Amsterdam, North Holland, Netherlands
Erasmus MC ( Site 0031)
Rotterdam, South Holland, Netherlands
Seoul National University Hospital-Internal Medicine ( Site 0702)
Seoul, South Korea
Severance Hospital, Yonsei University Health System-Medical oncology ( Site 0701)
Seoul, South Korea
Instituto Catalan de Oncologia - ICO ( Site 0044)
Barcelona, Spain
Hospital Universitario Fundacion Jimenez Diaz ( Site 0041)
Madrid, Spain
Centro Integral Oncologico Clara Campal START Madrid ( Site 0040)
Madrid, Spain
Hospital Universitario Quiron Madrid ( Site 0043)
Pozuelo de Alarcón, Madrid, Spain
National Taiwan University Hospital-Oncology ( Site 0801)
Taipei, Taiwan
Koo Foundation Sun Yat-Sen Cancer Center ( Site 0802)
Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.